Dominic , they have had remissions in special access patients...

Dominic , they have had remissions in special access patients (real people) strong cancer regression in some of the very first phse 1 patients , all those people with late stage cancer , considered terminal , strong reaction against psoriasis and other mounting evidence that would justify a much higher market cap and nothing happens . Then cure one little mouse and the price goes crazy . It is Australian biotech investors I dont understand . The big news will be from the upcomming phase 1 trials results in both cancer and psoriasis IMHO . Cheers .